NASDAQ:JANX Janux Therapeutics Q4 2023 Earnings Report $23.60 +0.88 (+3.87%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$23.50 -0.10 (-0.42%) As of 06/20/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Janux Therapeutics EPS ResultsActual EPS-$0.25Consensus EPS -$0.37Beat/MissBeat by +$0.12One Year Ago EPSN/AJanux Therapeutics Revenue ResultsActual Revenue$2.46 millionExpected Revenue$0.98 millionBeat/MissBeat by +$1.48 millionYoY Revenue GrowthN/AJanux Therapeutics Announcement DetailsQuarterQ4 2023Date3/8/2024TimeN/AConference Call DateFriday, March 8, 2024Conference Call Time7:00AM ETUpcoming EarningsJanux Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Janux Therapeutics Earnings HeadlinesJanux Therapeutics Becomes Oversold (JANX)June 20 at 8:32 AM | nasdaq.comCantor Fitzgerald Weighs in on JANX FY2026 EarningsJune 12, 2025 | americanbankingnews.comChaotic markets? No worries!As you may have seen over the last few weeks, I've been giving out special daily setups on my favorite ticker. We’ve been taking these setups @ 10AM and so far, we've posted 28 different payouts … Each of which were delivered at exactly 4PM as the market closed. You see, these setups require zero oversight and have shown the power to deliver in the most chaotic market conditions. And after a few weeks of fine-tuning … I knew it was time to let you in on The 4 PM Payout Plan. That's why Jack Carter and I pulled back the curtain to reveal how we've been able to nail in a 96% win rate in the same window the market lost 11 trillion dollars in value.June 21, 2025 | WealthPress (Ad)Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development OfficerMay 15, 2025 | finance.yahoo.comJanux Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | businesswire.comJanux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside PotentialMay 6, 2025 | finance.yahoo.comSee More Janux Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Janux Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Janux Therapeutics and other key companies, straight to your email. Email Address About Janux TherapeuticsJanux Therapeutics (NASDAQ:JANX), a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.View Janux Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Upcoming Earnings FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Wells Fargo & Company (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Interactive Brokers Group (7/15/2025)America Movil (7/15/2025)Citigroup (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
